EGFR and non-small cell lung carcinoma: EGFR mutations were mainly found between exon 18 to 21 in the coding region of tyrosine kinase, in which 46% of the ELREA amino acid sequence was missing in exon 19, and 35% to 45% of the L858R mutation in exon 21.[1,2] These 2 mutations are the types of mutations that are sensitive to small-molecule TKIs, and the clinical response rate of TKIs in NSCLC patients with sensitive mutations is 62% to 83%.[3–5] Approximately 10% of patients with EGFR mutations carry rare mutations.[6] There is little data on the sensitivity of these tumors to EGFR inhibitors with rare EGFR mutations.